3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
105
NIH
19
OTHER_GOV
3
INDUSTRY
2
Study Type
Observational
2
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Neoplasms
1
Interventions
pembrolizumab
1023
Carboplatin
964
Paclitaxel
933
Gemcitabine
794
Cisplatin
751
Docetaxel
683
Bevacizumab
609
Pemetrexed
502
Nivolumab
487
Cyclophosphamide
471
Capecitabine
461
Fluorouracil
418
Dexamethasone
403
Rituximab
372
Oxaliplatin
348
Injections
345
atezolizumab
298
Trastuzumab
298
Leucovorin
288
Cetuximab
282
Irinotecan
268
130-nm albumin-bound paclitaxel
254
Prednisone
245
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
fludarabine
218
Fulvestrant
217
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Magnetic Resonance Imaging
×
Clear all
NCT05191940
2026-03-20
LAPC
EBG MedAustron GmbH
Phase NA
Recruiting
30 enrolled
NCT04875871
2025-05-11
PARTICLE-PATHY
EBG MedAustron GmbH
Phase NA
Terminated
13 enrolled